14 research outputs found
The scandium effect in multicomponent alloys
Despite its excellent elemental properties, lightweight nature and good alloying potential, scandium has received relatively little attention in the manufacturing community. The abundance of scandium in the Earth's crust is quite high. It is more abundant than silver, cobalt, lead and tin. But, because scandium is so well dispersed in the lithosphere, it is notoriously difficult to extract in commercial quantities – hence low market availability and high cost. Scandium metallurgy is still a largely unexplored field – but progress is being made. This review aims to summarise advances in scandium metallurgical research over the last decade. The use of scandium as a conventional minor addition to alloys, largely in structural applications, is described. Also, more futuristic functional applications are discussed where details of crystal structures and peculiar symmetries are often of major importance. This review also includes data obtained from more obscure sources (especially Russian publications) which are much less accessible to the wider community. It is clear that more fundamental research is required to elevate the status of scandium from a laboratory-based curiosity to a mainstream alloying element. This is largely uncharted territory. There is much to be discovered
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
Separation of Strontium from Calcium with Potassium Rhodizonate...Application to Radiochemistry
Trace Analysis by Combination of Ion Exchange and X-Ray Fluorescence. Determination of Uranium in Sulfate Effluents
Train2Wind - Lollex and other results
• TRAIN2WIND is a PhD TRAINing school analysing enTRAINment in offshore WIND farms• The main aim is to investigate the inflow of new momentum into very large wind farms• 13 PhD students and 6 short-term fellows since 2020 (project is closing July 2024)• Lollex is the experiment at the Rødsand II wind farm in Lolland, Denmark (2 lidars on CTV Sept ‘22-Aug ‘23, plus a scanning lidar on the substation May-Aug ‘23)• We also investigate farm-farm interaction, and wether vertical axis wind turbines would be advantageous for GW+ wind farm